To edit, sign in as
Kelly Holloway
Kelly Holloway
Assistant Professor (status), University of Toronto
Verified email at - Homepage
Cited by
Cited by
Too few, too weak: conflict of interest policies at Canadian medical schools
A Shnier, J Lexchin, B Mintzes, A Jutel, K Holloway
PloS one 8 (7), e68633, 2013
Normalizing complaint: Scientists and the challenge of commercialization
KJ Holloway
Science, Technology, & Human Values 40 (5), 744-765, 2015
Uneasy subjects: Medical students' conflicts over the pharmaceutical industry
K Holloway
Social Science & Medicine 114, 113-120, 2014
‘Something there is that doesn’t love a wall’: Histories of the placental barrier
A Martin, K Holloway
Studies in History and Philosophy of Science Part C: Studies in History and …, 2014
Conflict of interest as ethical shorthand: understanding the range and nature of “non-financial conflict of interest” in biomedicine
Q Grundy, C Mayes, K Holloway, S Mazzarello, BD Thombs, L Bero
Journal of clinical epidemiology 120, 1-7, 2020
Health Canada needs to act on laboratory-developed diagnostics
K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth
CMAJ 191 (39), E1067-E1069, 2019
Blood donation and the global COVID‐19 pandemic: areas for social science research
J Haw, K Holloway, BM Masser, EM Merz, R Thorpe
Vox sanguinis, 2020
A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research
KHM Herder
Journal of Responsible Innovation, 2019
Dangerous diagnostics? Regulatory reform in the genomic era
K Holloway, FA Miller, A Gutierrez, S Hogarth
Bmj 364, 2019
Teaching conflict: Professionalism and medical education
KJ Holloway
Journal of bioethical inquiry 12 (4), 675-685, 2015
Half a century of Wilson & Jungner: reflections on the governance of population screening
S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ...
Wellcome Open Research 5, 2020
The Consultant's intermediary role in the regulation of molecular diagnostics in the US
K Holloway, FA Miller
Social Science & Medicine, 112929, 2020
A Troubled Solution: Medical Student Struggles with Evidence and Industry Bias
KJ Holloway
Science and engineering ethics 21 (6), 1673-1689, 2015
Patient advocacy, drug promotion, and the feminist paradox: An analysis of the Canadian Pain Coalition
K Holloway, J Haw
Health Tomorrow: Interdisciplinarity and Internationality 1 (1), 2013
Industry, experts and the role of the ‘invisible college’in the dissemination of non-invasive prenatal testing in the US
K Holloway, FA Miller, N Simms
Social Science & Medicine 270, 113635, 2021
9 Public Good, or Goods for the Public: The Commercialization of Academic Health Research
Health Matters: Evidence, Critical Social Science, and Health Care in Canada …, 2020
Responses to “Health Canada needs to act on laboratory-developed diagnostics”
K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth
CMAJ 192 (10), E261-E261, 2020
The Organized Response to the “War on Science” and the Lost Potential for Challenging Commercialization
K Holloway
TOPIA: Canadian Journal of Cultural Studies 36, 173-190, 2016
Emerging Researchers and Intellectual Property: Law, Policy and Practice
K Holloway
The Pharmaceutical Industry and Student Resistance: A Political Economy Perspective on Pharmaceutical Industry Influence in Medical Education in the United States and Canada
K Holloway
The system can't perform the operation now. Try again later.
Articles 1–20